Leerink Partners starts Eloxx Pharma coverage with Outperform
Leerink Partners initiated coverage of Eloxx Pharma with an Outperform rating and a $32.00 price target, implying 82.3% upside from the Sep 17 close of $17.55.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.